30161QAC8
Exelixis, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that makes cancer medicines, most notably cabozantinib, sold in the U.S. as CABOMETYX for kidney and liver cancers and as COMETRIQ for a rare thyroid cancer. Founded in 1994 by scientists from Yale and UC Berkeley who began by studying fruit flies and zebrafish to find drug targets, the company is now a fully integrated oncology drugmaker. Its name comes from the Greek word for "evolution," a nod to how the firm itself evolved from a genomics startup into a commercial drug company.
CONVERTIBLEUnderlying: EXELCUSIP: 30161QAC8HealthcareUS1 derivative reporter
4.25% Convertible Senior Subordinated Notes Due 2019
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
